Golidocitinib represents a groundbreaking Class 1 novel drug independently developed in China, marking the first highly selective small molecule inhibitor of JAK1 inhibitor globally approved for relapsed or refractory peripheral T-cell lymphoma. This evidence concerns the gene JAK1 and peripheral T-cell lymphoma, not otherwise specified.